Compare ARVN & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | SHEN |
|---|---|---|
| Founded | 2015 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 640.6M |
| IPO Year | 2018 | 1994 |
| Metric | ARVN | SHEN |
|---|---|---|
| Price | $6.82 | $10.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | $13.93 | ★ $27.50 |
| AVG Volume (30 Days) | 772.6K | ★ 1.1M |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.05% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | $262,600,000.00 | ★ $357,854,000.00 |
| Revenue This Year | $12.76 | $4.75 |
| Revenue Next Year | N/A | $5.17 |
| P/E Ratio | $4.04 | ★ N/A |
| Revenue Growth | N/A | ★ 9.08 |
| 52 Week Low | $6.80 | $9.67 |
| 52 Week High | $14.22 | $17.35 |
| Indicator | ARVN | SHEN |
|---|---|---|
| Relative Strength Index (RSI) | 28.59 | 33.46 |
| Support Level | N/A | N/A |
| Resistance Level | $8.52 | $12.61 |
| Average True Range (ATR) | 0.30 | 0.57 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 8.61 | 8.29 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.